(NASDAQ: ETON) Eton Pharmaceuticals's forecast annual revenue growth rate of 40.71% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 7.82%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.98%.
Eton Pharmaceuticals's revenue in 2026 is $80,775,000.On average, 5 Wall Street analysts forecast ETON's revenue for 2026 to be $3,073,597,911, with the lowest ETON revenue forecast at $2,935,811,232, and the highest ETON revenue forecast at $3,175,369,063. On average, 5 Wall Street analysts forecast ETON's revenue for 2027 to be $4,525,132,832, with the lowest ETON revenue forecast at $4,043,015,876, and the highest ETON revenue forecast at $5,056,089,027.
In 2028, ETON is forecast to generate $6,172,024,709 in revenue, with the lowest revenue forecast at $5,157,860,179 and the highest revenue forecast at $7,310,060,829.